34 results on '"Berger, Michael F."'
Search Results
2. Abstract PR07: MSI detection in plasma cfDNA: MSI as a marker of disease burden
3. Abstract A25: Cell-free DNA for noninvasive molecular profiling and response monitoring in pediatric cancers
4. Abstract 1752: BRCA-mediated tumorigenesis is origin and cell-type dependent
5. Abstract LB-304: Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis
6. Abstract 2736: A molecular and histopathologic map of cancer metastasis
7. Abstract 729: Zygosity, lineage, and penetrance dictate the role of germline pathogenicity in tumorigenesis
8. Abstract 1681: Prospective clinical sequencing distinguishes independent primary cancers from recurrent or metastatic disease
9. Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
10. Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
11. Abstract 729: Zygosity, lineage, and penetrance dictate the role of germline pathogenicity in tumorigenesis
12. Abstract 1681: Prospective clinical sequencing distinguishes independent primary cancers from recurrent or metastatic disease
13. Abstract 1672: Clinical validation of a genomics-based classifier to predict tissue of origin from targeted tumor sequencing
14. Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
15. Abstract 1752: BRCA-mediated tumorigenesis is origin and cell-type dependent
16. Abstract 2736: A molecular and histopathologic map of cancer metastasis
17. Abstract LB-304: Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis
18. Abstract 1672: Clinical validation of a genomics-based classifier to predict tissue of origin from targeted tumor sequencing
19. Abstract LB-228: Noninvasive profiling of molecular dynamics in patients receiving HER2 targeted therapies by cell-free DNA analysis
20. Abstract LB-227: Estimation of tumor-derived mutant allele fractions in cfDNA by shallow whole genome sequencing and fragment size analysis
21. Abstract 3024: Genomic characterization of organ-specific metastasis from prospective clinical sequencing of 20,000 cancer patients
22. Abstract B169: Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
23. Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer
24. Abstract 1281: Germline mutations inNBNconferring DNA damage response defects are found in patients with multiple cancer types
25. Abstract 971: Genome directed diagnosis informs clinical cancer care
26. Abstract 375: Oncologist use and perception of large panel next generation tumor sequencing
27. Abstract 4366: Identifying novel recurrent mutations reveals candidate actionable mutations
28. Abstract LB-320: Obligate lesions and diverse evolutionary patterns drive small cell bladder cancer
29. Abstract 119: Genomic analysis of remnant gastric adenocarcinoma
30. Abstract 602: Deleterious alterations in DNA damage response genes are associated with improved outcome in muscle-invasive bladder cancer patients treated with radiation-based bladder preservation
31. Abstract 610: Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing
32. Abstract LB-174: Examining the genomic differences between upper and lower tract urothelial carcinomas
33. Abstract SY16-03: Enterprise-wide clinical sequencing to match patients to personalized cancer treatments
34. Abstract 2742: Potential burden of germline findings in targeted tumor sequencing using matched normal DNA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.